Praxis Precision Medicines announced a proposed public offering of its common stock and, in lieu of common stock to certain investors, prefunded warrants to purchase shares of common stock. Piper Sandler is acting as lead book-running manager for the offering. Truist Securities is also acting as a book-runner for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRAX:
- Praxis Precision Medicines provides update on clinical stage portfolio
- Praxis enters licensing, collaboration agreement with Tenacia
- The biotech stocks to own in 2024, according to Piper Sandler
- 2 Best Stocks to Buy Now, 12/8/2023, According to Top Analysts
- Praxis Precision Medicines trading halted, news pending